Advancing bnAb combinations for HIV prevention
- PMID: 37802563
- DOI: 10.1016/S2352-3018(23)00172-8
Advancing bnAb combinations for HIV prevention
Conflict of interest statement
HG and PS are inventors on patent applications on neutralising antibodies and have received payments from the University Hospital Cologne for licensed antibodies.
Comment on
-
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial.Lancet HIV. 2023 Oct;10(10):e653-e662. doi: 10.1016/S2352-3018(23)00140-6. Lancet HIV. 2023. PMID: 37802566 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
